LTRN · Lantern Pharma Inc. · Financials
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company's ability to continue as a going concern in the absence of obtaining substantial additional funding. While the Company plans to pursue periodic capital raises, including additional potential sales under the ATM, as well as potential collaborations, grant funding and other opportunities to extend the Company's operating runway, no assurance can be given that sufficient funding will be available when needed to allow the Company to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| $8.7M | $11.51M | $16.13M | $11.89M | $8.6M | $7.57M | $2.24M | — | |
| $6.77M | $6.46M | $6.09M | $5.98M | $5.83M | $5.02M | $3.66M | $1.48M | |
| $15.81K | $17.28K | $17.28K | $14.62K | $10.08K | $6761 | $3388 | $1627 | |
| $15.47M | $17.98M | $22.22M | $17.88M | $14.43M | $12.59M | $5.91M | $2.43M | |
| -$15.47M | -$17.98M | -$22.22M | -$17.88M | -$14.43M | -$12.59M | — | — | |
| $176.37K | $421.13K | $692.87K | $1.15M | -$31.55K | $160.55K | — | — | |
| -$18.65M | -$17.12M | -$20.78M | -$15.96M | -$14.26M | -$12.36M | -$5.91M | -$2.43M | |
| $14.03M | — | — | — | — | $12.36M | $5.91M | — | |
| -$14.03M | — | — | — | — | -$12.36M | -$5.91M | — | |
| -$18.74M | -$17.25M | -$20.52M | -$15.7M | -$14.54M | -$12.46M | — | — | |
| USD/shares | -$1.62 | -$1.57 | -$1.93 | -$1.47 | -$1.31 | -$1.13 | — | — |
| USD/shares | -$1.62 | -$1.57 | -$1.93 | -$1.47 | -$1.31 | — | — | — |
| shares | — | 10.9M | 10.76M | 10.84M | 10.85M | 10.9M | 4.3M | 1.98M |
| shares | — | 10.9M | 10.76M | 10.84M | 10.85M | 10.9M | 4.3M | 1.98M |
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2021–FY2023: $3.92M in buybacks.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 246 similar-size Biotechnology companies (of 534 listed).